LVR-Klinik Köln, Cologne, Germany.
Curr Opin Psychiatry. 2013 Jan;26(1):47-53. doi: 10.1097/YCO.0b013e32835a5947.
This article reviews literature published over the period January 2011-June 2012 on biomarkers in major depression.
Although a large body of research accumulated over the past decades points to distinct biological mechanisms being involved in the pathophysiology of major depressive disorder (MDD), its precise pathobiology is not yet fully understood. In the last 2 years, substantial new research has been generated in an attempt to identify and characterize novel candidate biomarkers for MDD. This review provides an update on biomarker research in MDD and summarizes the most recent results from neuroimaging, genetic, epigenetic, and neurochemical studies in MDD.
Promising new findings report high diagnostic accuracy for metabonomic and epigenetic approaches as well as combinatorial functional neuroimaging approaches, which are currently representing the forefront of MDD biomarker development.
本文综述了 2011 年 1 月至 2012 年 6 月期间发表的关于重度抑郁症生物标志物的文献。
尽管过去几十年积累的大量研究表明，在重度抑郁症（MDD）的病理生理学中存在不同的生物学机制，但它的确切病理生物学尚未完全了解。在过去的 2 年中，大量的新研究试图确定和描述 MDD 的新型候选生物标志物。本综述提供了 MDD 生物标志物研究的最新进展，并总结了神经影像学、遗传学、表观遗传学和神经化学研究中 MDD 的最新结果。
有希望的新发现报告了代谢组学和表观遗传方法以及组合功能神经影像学方法具有很高的诊断准确性，这些方法目前代表了 MDD 生物标志物开发的前沿。
